Improved combination chemotherapy in advanced gastric cancer.

Levi, John A.; Dalley, D.; Aroney, R. S.

doi:10.1136/bmj.2.6203.1471

Cited by 57 publications

(9 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…FAB regimen appears to be an active com bination that is able to induce an objective response in about 50% of the adequately treated patients, with a significant increase in median survival of responding patients over nonresponders. Similar results were re ported by Levi et al [8] in 2 series of patients treated with a slightly modified FAB. Initially, they achieved an overall response rate of 52% in 35 patients; median survival for responding patients was 12 months with 30% still living at 20 months.…”

Section: Discussionsupporting

confidence: 79%

Treatment of Advanced Measurable Gastric Carcinoma with 5-Fluorouracil, Adriamycin, and BCNU

López¹,

Lauro²,

Papaldo³

et al. 1986

Oncology

View full text Add to dashboard Cite

61 patients with advanced measurable gastric carcinoma were treated with 5-fluorouracil, adriamycin and BCNU (FAB). Of 50 evaluable patients, 48% achieved a response (3 complete and 21 partial responses), and 24% experienced disease stabilization. The median duration of response was 9 months, and median survival of all patients was 7 months. Responding patients survived significantly longer than nonresponders (p <0.001). Toxicity was generally mild to moderate, rarely requiring dose reduction or prolongation of treatment intervals. These results indicate that FAB regimen is an active combination in metastatic or locally advanced gastric cancer, and can be used as first-line treatment in patients with this disease.

show abstract

Section: Discussionsupporting

confidence: 79%

Treatment of Advanced Measurable Gastric Carcinoma with 5-Fluorouracil, Adriamycin, and BCNU

López¹,

Lauro²,

Papaldo³

et al. 1986

Oncology

View full text Add to dashboard Cite

show abstract

“…More effective treatments use a combination of two, three or more chemotherapy drugs. Combining two chemotherapy drugs has been examined by Levi et al and response rates for drug cocktails increased to 40-50% (Levi et al, 1979). McDonald et al combined three chemotherapy drugs fluorouracil, doxorubicin, and mitomycin and results showed a 55% response rate (Levi et al, 1979).…”

Section: Introductionmentioning

confidence: 99%

“…Combining two chemotherapy drugs has been examined by Levi et al and response rates for drug cocktails increased to 40-50% (Levi et al, 1979). McDonald et al combined three chemotherapy drugs fluorouracil, doxorubicin, and mitomycin and results showed a 55% response rate (Levi et al, 1979). Rivera et al studied docetexal, a newer chemotherapy drug, in combination with cisplatin and 5-fluorouracil (DCF).…”

Section: Introductionmentioning

confidence: 99%

“…Efficacy of these drugs are typically measured via clinical response rates, which is the percentage of patients that respond to cancer treatment such that cancer cells are no longer detected. The response rates to these drugs were poor ranging from 15-35% (Cleveland Clinic Foundation, 2010;Hershock, 2006;Levi et al, 1979). More effective treatments use a combination of two, three or more chemotherapy drugs.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

A Tunable Microfluidic Device for Drug Delivery

Adams¹,

Yang²,

Gress³

et al. 2012

Advances in Microfluidics

View full text Add to dashboard Cite

“…FAM und FAM-modified schedules are those most widely used in the chemotherapy of advanced gastric cancer, suggest ing response rates of 15-40% [1][2][3][4][5][6][7][8][9][10]. Further regimens, such as EAP [11] and FAMTX [12][13][14], show response rates up to 50%.…”

Section: Introductionmentioning

confidence: 99%

Combined Epirubicin, 5-Fluorouracil and Folinic Acid with Allopurinol Protection for Second-Line Treatment of Advanced Gastric Cancer: A Pilot Study

Tsavaris¹,

Mylonakis²,

Bacoyiannis³

et al. 1995

Oncol Res Treat

View full text Add to dashboard Cite

Background: The combination of 5-fluorouracil (5-FU) and folinic acid (FA) has demonstrated activity in most gastrointestinal tumors. The addition of epirubicin (Epi) could increase the efficacy of the combination. This was examined in patients with advanced gastric cancer who had previously received chemotherapy with FAM (5-FU + adriamycin + mitomycin) and relapsed. Patients and Method: The schedule was conducted in 30 patients who had previously received FAM. It consisted of FA 200 mg/m2/day intravenous push administration prior to 5-FU infusion 600 mg/m2/day in 500 ml 5 % normal saline over 1 h for 5 days; Epi 35 mg/m2/day intravenous bolus before FA + 5-FU administration on days 1 and 2. Additionally, allopurinol (AL) 300 mg, 1 tablet × 3/day, started 2 days before treatment for 17 days. The cycle was repeated every 28 days. Results: The sites of the largest measurable lesion included local relapse in 19 patients, liver metastases in 17, and lymph node metastases in 16 patients. Pretreatment characteristics included: age 33-72 (median 63) years, and Karnofsky Performance Status of 80-90%. All patients were evaluable for response and toxicity. Objective tumor responses (partial responses) were seen in 8 of 30 patients (26%) (5 had previously stable diseases and 3 partial responses to FAM). The estimated median survival was 21.8 weeks measured from the onset of therapy, duration of response was 13.6 weeks and time to progression, 19 weeks. Toxocity resulted primarily in nausea and vomiting, diarrhea, alopecia, myelosuppression, and mucositis. Conclusion: We conclude that this second-line combination of Epi + FA + 5-FU with AL protection has moderate activity and increased toxicity in the treatment of advanced gastric cancer.

show abstract

Improved combination chemotherapy in advanced gastric cancer.

Cited by 57 publications

References 5 publications

Treatment of Advanced Measurable Gastric Carcinoma with 5-Fluorouracil, Adriamycin, and BCNU

Treatment of Advanced Measurable Gastric Carcinoma with 5-Fluorouracil, Adriamycin, and BCNU

A Tunable Microfluidic Device for Drug Delivery

Combined Epirubicin, 5-Fluorouracil and Folinic Acid with Allopurinol Protection for Second-Line Treatment of Advanced Gastric Cancer: A Pilot Study

Contact Info

Product

Resources

About